Restricted accessResearch articleFirst published online 2017-04
Development of a Qualitative Quantitative Polymerase Chain Reaction Test to Identify Patients Failing First-Line Therapy to Non-Nucleotide Reverse Transcriptase Inhibitor
Antiretroviral therapy (ART) can be compromised by selection of drug resistance strains, which can be promoted by lack of adherence during therapy and drug tolerance, and some of these drug-resistant strains can persist for years as minority populations. The K103N drug resistance mutation is selected by the use of non-nucleotide reverse transcriptase inhibitors, including nevirapine or efavirenz (EFV), used in low-income countries. Here we describe the use of a less expensive qualitative point mutation polymerase chain reaction (PMqPCRK103N) targeting K103N mutation. To validate the use of this methodology, we tested previously sequenced samples from patients treated with highly active ART with viral loads above 2,000 copies/ml and compared the results of our assay with Illumina deep sequencing. Due to its low cost and high specificity, this test is particularly suitable for low-income countries to screen for pretreatment resistance in patients either initiating ART or failing first-line regimens containing EFV.
Get full access to this article
View all access options for this article.
References
1.
AraujoAF, BritesC, Monteiro-CunhaJ, SantosLA, Galvao-CastroB, AlcantaraLCJ: Lower prevalence of human immunodeficiency virus type 1 Brazilian subtype B found in northeastern Brazil with slower progression to AIDS. AIDS Res Hum Retroviruses, 2010; 26:1249–1254.
2.
ArcherJ, WeberJ, HenryK, WinnerD, GibsonR, LeeL, et al.: Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One, 2012; 7:e49602.
3.
SantoroMM, PernoCF: Review article. HIV-1 genetic variability and clinical implications. ISRN Microbiol, 2013; 2013;article ID 481314.
4.
BoothCL, Garcia-diazAM, YouleMS, JohnsonMA, PhillipsA, GerettiAM: Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother, 2007; 59:517–524.
5.
BulteelN, Bansi-MatharuL, ChurchillD, DunnD, BibbyD, HillT, et al.: The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK collaborative HIV cohort. J Infect, 2014; 68:77–84.
6.
WeinstockHS, ZaidiI, HeneineW, BennettD, Garcia-lermaJG, DouglasJM, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1—infected persons in 10 US cities. J Infect Dis, 2004; 189:2174–2180.
7.
VairoF, NicastriE, LiuzziG, ChaulaZ, NguhuniB, BevilacquaN, et al.: HIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania. BMC Infect Dis, 2013; 13:439.
8.
LiJZ: HIV-1 drug-resistant minority variants: Sweating the small stuff. J Infect Dis, 2014; 209:639–641.
9.
KimMH, SongJE, AhnJY, KimYC, OhDH, ChoiH, et al.: HIV antiretroviral resistance mutations among antiretroviral treatment-naive and -experienced patients in South Korea. AIDS Res Hum Retroviruses, 2013; 29:1617–1620.
10.
CastroH, PillayD, CaneP, AsboeD, CambianoV, PhillipsA, et al.: Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis, 2013; 208:1459–1463.
11.
DescampsD, AssoumouL, ChaixM, ChaillonA, PakianatherS, DeA, et al.: National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001–2011. J Antimicrob Chemother, 2013; 68:2626–2631.
12.
ReisG, AlcaKC: Polymorphisms in the HIV-1 gp41 env gene, natural resistance to enfuvirtide (T-20) and pol resistance among pregnant Brazilian women. J Med Virol, 2014; 86:8–17.
13.
JohnsonJA, LiJ, WeiX, LipscombJ, BennettD, BrantA, et al.: Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One, 2007; 2:e638.
14.
PanosG, CharatsisG, PaparizosV, KazantziM, FalagasME: Prevalence of genotypic resistance to nucleoside analogues, and protease inhibitors in HIV-infected persons in Athens, Greece. AIDS Res Hum Retroviruses, 2008; 24:43–51.
15.
KarimQA, BaneguraA, CahnP, ChristieCDC, DintruffR, DistelM, et al.: Asking the right questions: Developing evidence- based strategies for treating HIV in women and children. BMC Public Health, 2011; 11:388.
16.
PérezH, VignolesM, LauferN, GómezA, CollP, LattnerJ, RolónM, SalomónH, CahnP: Short communication. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen. Antivir Ther, 2008; 13:135–139.
17.
JohnsonJA, LiJ, WeiX, LipscombJ, IrlbeckD, CraigC, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment—naive populations and associate with reduced treatment efficacy. PLos Med, 2008; 5:e158.
18.
DeeksSG: Transmitted minority drug-resistant HIV variants: A new epidemic?. PLoS Med, 2008; 5:e164.
BellecaveP, Recordon-PinsonP, PapuchonJ, VandenhendeM-A, ReigadasS, TauzinB, et al.: Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals. AIDS Res Hum Retroviruses, 2014; 30:170–173.
21.
IyerS, CaseyE, BouzekH, KimM, DengW, LarsenBB, et al.: Comparison of major and minor viral SNPs identified through single template sequencing and pyrosequencing in acute HIV-1 infection. J Clin Virol, 2015; 70:95–100.
22.
FonagerJ, LarssonJT, HussingC, EngsigFN, NielsenC, FischerTK: Identification of minority resistance mutations in the HIV-1 integrase coding region using next generation sequencing. J Clin Virol, 2015; 73:95–100.
23.
TodescoE, RodriguezC, Morand-JoubertL, Mercier-DartyM, DesireN, WirdenM, et al.: Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. J Antimicrob Chemother, 2014; 70:1503–1506.
24.
LinNH, KuritzkesDR: NIH public access. Curr Opin HIV AIDS, 2009; 4:481–487.
25.
SánchezV, MasiáM, RobledanoC, PadillaS, RamosJM, GutiérrezF: Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay. J Clin Microbiol, 2010; 48:4135–4139.
26.
SvicherV, ArrigoRD, AlteriC, AndreoniM, AngaranoG, AntinoriA, et al.: Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: Results from the OSCAR study group. New Microbiol, 2010; 33:195–206.
LipscombJT, SwitzerWM, LiJ, MasciotraS, MicheleS, JohnsonJA, et al.: HIV reverse transcriptase drug resistance mutations during early infection reveal greater transmission diversity than in Env. J Infect Dis, 2014; 210:1827–1837.
29.
AntoniadouZ, HezkaJ, KousiappaI, MamaisI, SkouraL: Short communication. Cellular HIV-1 DNA levels are equivalent among drug sensitive and drug resistant strains in newly diagnosed and antiretroviral naive patients. AIDS Res Hum Retroviruses, 2014; 30:266–271.
30.
ParyanM, Mohammadi-YeganehS, Mirab SamieeS, RezvanH: Design and development of a multiplex real-time PCR assay for detection of HIV-1 and HCV using molecular beacons. Indian J Microbiol, 2012; 52:456–463.
31.
JalavaK, RintalaH, OllgrenJ, MaunulaL, Gomez-AlvarezV, RevezJ, et al.: Novel microbiological and spatial statistical methods to improve strength of epidemiological evidence in a community-wide waterborne outbreak. PLoS One, 2014; 9:e104713.
32.
HarrisJR, MarstonBJ, SangrujeeN, DuPlessisD, ParkB: Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP). PLoS One, 2011; 6:e23158.
33.
GumedeN, LentsoaneO, BurnsCC, PallanschM, de GourvilleE, YogoleloR, et al.: Emergence of vaccine-derived polioviruses, Democratic Republic of Congo, 2004–2011. Emerg Infect Dis, 2013; 19:1583–1589.
34.
BhargavaM, CajasJM, WainbergMA, KleinMB, PaiNP: Review article. Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. J Int AIDS Soc, 2014; 17:18944.
35.
BoullosaJ, BachuM, BilaD, RangaU, SüffertT, SasazawaT, et al.: Genetic diversity in HIV-1 subtype C LTR from Brazil and Mozambique generates new transcription factor-binding sites. Viruses, 2014; 6:2495–2504.
36.
SiemieniukRAC, BecktholdB, GillMJ, ChbMB, SiemieniukRAC, BecktholdB, et al.: Increasing HIV subtype diversity and its clinical implications in a sentinel North American population. Can J Infect Dis Med Microbiol, 2013; 24:69–73.
37.
CushingA, FlahertyP, HopmansE, BellJM, JiHP: RVD: A command-line program for ultrasensitive rare single nucleotide variant detection using targeted next-generation DNA resequencing. BMC Res Notes, 2013; 6:206.
38.
EkiciH, RaoSD, SönnerborgA, RamprasadVL, GuptaR, NeogiU: Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: Implications for use in low- and middle-income countries. J Antimicrob Chemother, 2014; 69:3349–3355.
39.
LuthraR, PatelKP, ReddyNG, HaghshenasV, RoutbortMJ, HarmonMA, et al.: Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: Applicability for diagnostics and disease monitoring. Haematologica, 2014; 99:465–473.
40.
QuailMA, SmithM, CouplandP, OttoTD, HarrisSR, ConnorTR, et al.: A tale of three next generation sequencing platforms: Comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics, 2012; 13:341.
41.
NewcombeRG: Interval estimation for the difference between independent proportions: Comparison of eleven methods. Stat Med, 1998; 17:873–890.
42.
Brasil Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Recomendações para Terapia Anti–retroviral em Adultos Infectados pelo. HIV, 2008; 7Ed:34–51.
43.
HauserA, MugenyiK, RoseK, BluethgenK, HarmsG, KunzA, et al.: Detection and quantification of minor HIV-1 variants harbouring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob Agents Chemother, 2009; 53:2965–2973.
44.
DelobelP, SaliouA, NicotF, DuboisM, TrancartS, TangreP, et al.: Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One, 2011; 6:e21655.
45.
PersaudD, BedriA, ZiemniakC, MoorthyA, GudettaB, AbashawlA, et al.: Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. AIDS Res Hum Retroviruses, 2011; 27:823–829.
46.
KuhnL, HuntG, TechnauK-G, CoovadiaA, LedwabaJ, PickerillS, et al.: Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS, 2014; 28:1673–1678.
47.
HolguínÁ, YebraG, MartínL, de PinedaAT, RuizLE, QuezadaAY, NietoAL, EscobarG: Transmitted drug-resistance in human immunodeficiency virus-infected adult population in El Salvador, Central America. Clin Microbiol Infect, 2013; 19:E523–E532.
48.
LelR, NgairaJ, LihanaR, KhamadiS: HIV-1 drug resistance mutations among infants born to HIV-positive mothers in Busia, Kenya. AIDS Res Hum Retroviruses, 2014; 30:11–13.
49.
JohnsonJA, LiJ, MorrisL, MartinsonN, GrayG, McintyreJ, et al.: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dsi, 2005; 192:16–23.
50.
VandenhendeM-A, BellecaveP, Recordon-PinsonP, ReigadasS, BidetY, BruyandM, et al.: Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure. PLoS One, 2014; 9:e86771.
51.
AghokengAF, MonleauM, Eymard-DuvernayS, DagnraA, KaniaD, Ngo-Giang-HuongN, et al.: Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis, 2014; 58:99–109.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
